Johnson & Johnson $JNJ Position Raised by Donoghue Forlines LLC

Donoghue Forlines LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 119.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,816 shares of the company’s stock after purchasing an additional 11,328 shares during the period. Johnson & Johnson accounts for about 1.2% of Donoghue Forlines LLC’s holdings, making the stock its 8th biggest position. Donoghue Forlines LLC’s holdings in Johnson & Johnson were worth $3,860,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. CFC Planning Co LLC grew its stake in Johnson & Johnson by 5.9% in the 3rd quarter. CFC Planning Co LLC now owns 19,357 shares of the company’s stock valued at $3,589,000 after buying an additional 1,077 shares in the last quarter. Resonant Capital Advisors LLC boosted its holdings in shares of Johnson & Johnson by 5.6% in the third quarter. Resonant Capital Advisors LLC now owns 31,647 shares of the company’s stock worth $5,868,000 after acquiring an additional 1,686 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Johnson & Johnson by 1,013.7% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 6,582 shares of the company’s stock valued at $1,216,000 after purchasing an additional 5,991 shares in the last quarter. Lmcg Investments LLC raised its stake in shares of Johnson & Johnson by 13.2% during the 3rd quarter. Lmcg Investments LLC now owns 64,050 shares of the company’s stock valued at $11,876,000 after purchasing an additional 7,471 shares during the period. Finally, Walkner Condon Financial Advisors LLC lifted its holdings in Johnson & Johnson by 16.0% during the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 3,819 shares of the company’s stock worth $708,000 after purchasing an additional 528 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ opened at $218.09 on Wednesday. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $220.11. The company has a market capitalization of $525.43 billion, a P/E ratio of 21.05, a P/E/G ratio of 2.25 and a beta of 0.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm’s 50 day simple moving average is $206.92 and its 200 day simple moving average is $188.05.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 50.19%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive Phase 3 results for CAPLYTA (major psychiatric drug) showed stronger remission outcomes, lifting biotech/pharma sentiment around JNJ. CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says
• Positive Sentiment: Robotic surgery business and a recent regulatory submission are cited as supporting JNJ’s dividend-growth outlook, reinforcing income-investor interest. Robotic surgery fuels Johnson & Johnson dividend growth outlook
• Positive Sentiment: High-profile bullish coverage: Jim Cramer has been increasingly positive on JNJ, noting strength in the cancer portfolio and framing JNJ as a core holding — a boost to retail sentiment. Jim Cramer Says He Was Wrong for Selling Johnson & Johnson for the Charitable Trust
• Positive Sentiment: Market commentary points to JNJ nearing a 52-week high as CAPLYTA data and earnings momentum lift near-term upside expectations. Johnson & Johnson Near 52-Week High As CAPLYTA Data Boosts Sentiment
• Neutral Sentiment: Analyst previews ahead of Q4 (earnings due Jan 21) are broadly constructive — core pharma and MedTech strength cited, but Q4/2026 guidance is the key near-term catalyst. Johnson & Johnson Q4 preview: Strength in core portfolio keeps analysts bullish
• Neutral Sentiment: Coverage pieces detail ways to generate income from JNJ shares and options ahead of earnings — increased retail/options activity could amplify intraday moves. How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings
• Neutral Sentiment: Index/sector coverage notes JNJ’s MedTech reach on Dow-related indices — supportive for passive flows but not an immediate price catalyst. Johnson & Johnson (NYSE:JNJ) Dow Jones Index Medical Technology Reach
• Negative Sentiment: Broader market “risk-off” (Davos/Trump headlines) pressured US equities today, which weighed on JNJ despite company-specific gains. Markets Switch to “Risk-Off” Ahead of Trump at Davos
• Negative Sentiment: Analysts and previews flag near-term risks: Stelara biosimilar competition and China headwinds could pressure growth and margin recovery in 2026. Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?
• Negative Sentiment: Outlook risk: commentary warns 2026 guidance will be a big test for JNJ’s valuation — missed targets or cautious guidance could trigger a pullback. Johnson & Johnson’s $10 Billion Test: 2026 Outlook Could Make Or Break JNJ Heading Into Q4

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Loop Capital set a $190.00 target price on Johnson & Johnson in a report on Wednesday, October 22nd. Citigroup boosted their price objective on shares of Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. HSBC restated a “buy” rating and set a $240.00 price target on shares of Johnson & Johnson in a research report on Wednesday, December 10th. Finally, UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $213.33.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.